NCT04638582 2026-04-17
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Terminated
McGill University Health Centre/Research Institute of the McGill University Health Centre
ImmunityBio, Inc.